Table 2. Clinical Characteristics and Management of Mogamulizumab-Associated Rash.

Patient No.	Clinical presentation				Anatomical region				Symptoms (moderate-severe pruritus)	MAR management					Skin biopsy (histopathologic patterns identified)
	F-MF–like scalp plaques with alopecia	Papules and/or plaquesa	Photoaccentuated	Morbilliform or erythrodermic	Head and neck	Trunk	Arms	Legs		Topical corticosteroids	Systemic corticosteroids	Methotrexate	Continued	Discontinued
1b	X				Xc	X				X			X		Psoriasiform, spongiotic, interface
2b			X		X	X	X		X	X	X			X	Psoriasiform, spongiotic, granulomatous, lichenoid
3		X		X	Xc	X	X	X	X	X	X			X	Psoriasiform, spongiotic, interface
4		X				X	X	X	X	X	X	X		X	Granulomatous
5		X	X	X	Xc	X	X	X	X	X	X			X	Psoriasiform, spongiotic, granulomatous, interface
6				X	X	X	X	X		X	X	X		X	Spongiotic, lichenoid, interface
7	X				Xc	X				X				X	Spongiotic
8				X	X	X	X	X	X	X	X			X	Spongiotic, granulomatous
9b		X				X				X			X		Psoriasiform, spongiotic, granulomatous, lichenoid
10			X		X	X	X	X	X	X	X	X	Xd		Interface, lichenoid
11	X				Xc				X	X	X	X		X	Spongiotic, lichenoid, interface
12	X				Xc		X		X	X	X	X		X	Lichenoid, spongiotic
13	X				Xc	X				X			X		Psoriasiform, spongiotic
14		X			Xc	X	X			X		X		X	Spongiotic
15	X				Xc					X			X		Spongiotic, interface
16	X				Xc				X	X				X	Spongiotic
17		X			Xc	X	X	X	X	X	X	X		X	Psoriasiform, spongiotic
18b			X	X	X	X	X	X	X	X	X			X	Psoriasiform, spongiotic, interface
19b	X		X		Xc	X	X		X	X	X			X	Spongiotic
Total No. (N = 19)	8	6	5	5	17	15	12	8	12	19	12	7	5	14	NA

Abbreviations: F-MF, folliculotropic mycosis fungoides; MAR, mogamulizumab-associated rash; NA, not applicable.

^aVariable morphologic findings, including psoriasiform, lichenoid, or smooth indurated papules and/or plaques.

^bPatient was enrolled in the Mogamulizumab Versus Vorinostat in Previously Treated Cutaneous T-Cell Lymphoma (MAVORIC) clinical trial.

^cProminent scalp involvement.

^dMogamulizumab-associated rash had a delayed onset of 2 months after last dose of mogamulizumab.